Drug intelligence / Profile preview

TERT activation gene therapy

Development stage: Preclinical
Lead developer: Elixirgen Therapeutics
Modality: Gene Therapies
Administration: Intranasal, Intravenous, Intrathecal, Direct Organ Injection

Overview

TERT activation gene therapy is a regenerative medical intervention designed to increase the expression and activity of telomerase reverse transcriptase (TERT). Developed and offered by Integrated Healthcare Systems (Integrated Health Systems) as part of a concierge medical service, this gene therapy aims to maintain or lengthen telomeres, thereby supporting cellular replicative capacity and potentially addressing age-related conditions. By upregulating TERT, the therapy seeks to counteract the natural shortening of telomeres that occurs during cell division, which is a hallmark of biological aging.

Other names: TERTtelomerase activation

Targets

TERT (Telomerase)

Beyond the preview

Go deeper on TERT activation gene therapy.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TERT activation gene therapy.

Explore the full profile